Anti-Ageing GH Claims
Anti-ageing growth hormone claims extrapolate the age-related decline in GH pulse amplitude into a rejuvenation therapy that controlled trials have consistently failed to support.
Growth hormone secretion falls with age, mostly through reduced pulse amplitude rather than lost pulse frequency, and IGF-1 falls with it. That observation, sometimes labelled somatopause, is the entire biological premise of anti-ageing growth hormone marketing.
The founding citation is a 1990 New England Journal of Medicine report by Rudman of twelve men over sixty given growth hormone for six months, which found a gain in lean body mass of roughly nine percent and a fall in fat mass of about fourteen percent. It measured no strength, no function and no clinical endpoint, and the journal later published an editorial objecting to the study's promotional misuse. The controlled literature that followed is far less encouraging: a 2007 systematic review in Annals of Internal Medicine pooled trials in healthy older adults and found small body-composition shifts with no improvement in strength, alongside markedly higher rates of oedema, arthralgia, carpal tunnel syndrome and impaired glucose tolerance.
The regulatory position is unusually explicit. In the United States growth hormone is subject to a drug-specific criminal provision that makes distribution for anti-ageing, athletic or other unapproved indications a federal offence rather than a labelling infraction. No regulator anywhere has approved growth hormone or any secretagogue for ageing.
The specific error is not that growth hormone does nothing, but that shifting the ratio of fat to lean tissue has been substituted for the endpoint anyone cares about, which is function. A countervailing line of evidence also goes unmentioned: reduced growth hormone and IGF-1 signalling extends lifespan in several model organisms, and follow-up of cohorts with growth hormone receptor deficiency has found strikingly low rates of cancer and diabetes.